Journal article
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp, Laura Senovilla, Ilio Vitale, Erika Vacchelli, Sandy Adjemian, Patrizia Agostinis, Lionel Apetoh, Fernando Aranda, Vincenzo Barnaba, Norma Bloy, Laura Bracci, Karine Breckpot, David Brough, Aitziber Buque, Maria G Castro, Mara Cirone, Maria I Colombo, Isabelle Cremer, Sandra Demaria, Luciana Dini Show all
OncoImmunology | TAYLOR & FRANCIS INC | Published : 2014
Abstract
Apoptotic cells have long been considered as intrinsically tolerogenic or unable to elicit immune responses specific for dead cell-associated antigens. However, multiple stimuli can trigger a functionally peculiar type of apoptotic demise that does not go unnoticed by the adaptive arm of the immune system, which we named "immunogenic cell death" (ICD). ICD is preceded or accompanied by the emission of a series of immunostimulatory damage-associated molecular patterns (DAMPs) in a precise spatiotemporal configuration. Several anticancer agents that have been successfully employed in the clinic for decades, including various chemotherapeutics and radiotherapy, can elicit ICD. Moreover, defects..
View full abstractGrants
Awarded by Cancer Research UK
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Funding Acknowledgements
GL and LG are supported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).